Author Title [ Type(Desc)] Year
Filters: Author is Malcovati, Luca  [Clear All Filters]
Journal Article
Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Cañizo C, Porta MGDella, Fenaux P, Gattermann N, Germing U, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013.
Kiesewetter B, Cherny NI, Boissel N, Cerisoli F, Dafni U, de Vries EGE, Ghia P, Gökbuget N, González-Calle V, Huntly B, et al. EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. ESMO Open. 2020;5(1).
Malcovati L, Ambaglio I, Elena C. The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications. Curr Opin Oncol. 2015.
Stojkov K, Silzle T, Stussi G, Schwappach D, Bernhard J, Bowen D, Cermak J, Dinmohamed AG, Eeltink C, Eggmann S, et al. Guideline-based indicators for adult patients with myelodysplastic syndromes. Blood Adv. 2020;4(16):4029-4044.
Pellagatti A, Benner A, Mills KI, Cazzola M, Giagounidis A, Perry J, Malcovati L, Porta MGDella, Jadersten M, Verma A, et al. Identification of Gene Expression-Based Prognostic Markers in the Hematopoietic Stem Cells of Patients With Myelodysplastic Syndromes. J Clin Oncol. 2013.
Onida F, Barosi G, Leone G, Malcovati L, Morra E, Santini V, Specchia G, Tura S. Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups. Haematologica. 2013;98(9):1344-52.
Asimomitis G, Deslauriers AG, Kotini AG, Bernard E, Esposito D, Olszewska M, Spyrou N, Ossa JEsteban Ar, Mortera-Blanco T, Koche RPatrick, et al. Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs. Blood Adv. 2022.
Porta MGDella, Alessandrino EPaolo, Bacigalupo A, van Lint MTeresa, Malcovati L, Pascutto C, Falda M, Bernardi M, Onida F, Guidi S, et al. Predictive factors for the outcome of allogeneic transplantation in patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System (IPSS-R). Blood. 2014.
Koreth J, Pidala J, Perez WS, H Deeg J, Garcia-Manero G, Malcovati L, Cazzola M, Park S, Itzykson R, Ades L, et al. Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. J Clin Oncol. 2013.